efegatran has been researched along with acetylphenylalanyl-prolyl-boroarginine in 2 studies
| Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) | Studies (acetylphenylalanyl-prolyl-boroarginine) | Trials (acetylphenylalanyl-prolyl-boroarginine) | Recent Studies (post-2010) (acetylphenylalanyl-prolyl-boroarginine) |
|---|---|---|---|---|---|
| 43 | 3 | 0 | 30 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callas, DD; Fareed, J | 1 |
| Verstraete, M | 1 |
1 review(s) available for efegatran and acetylphenylalanyl-prolyl-boroarginine
| Article | Year |
|---|---|
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
1 other study(ies) available for efegatran and acetylphenylalanyl-prolyl-boroarginine
| Article | Year |
|---|---|
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |